Known targets — ChEMBL curated mechanism
FLT1FLT3FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Su-014813. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 12/20 | 0.93 |
| ▸ | PDGFRB known ✓ | P09619 | 11/20 | 0.93 |
| ▸ | KIT known ✓ | P10721 | 4/20 | 0.93 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 0.93 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.93 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.93 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.93 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.93 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.93 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.93 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.93 |
| ▸ | RIOK2 | Q9BVS4 | 3/20 | 0.93 |
| ▸ | TLK1 | Q9UKI8 | 3/20 | 0.93 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.93 |
| ▸ | PLK4 | O00444 | 3/20 | 0.93 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.93 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.93 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.93 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.93 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Su-014813 SCHEMBL3367375 | 1.00 | KDR (0.93) | KDRPDGFRBPRKAA1FGFR1PRKAA2 | |
| Su-014813 SCHEMBL30030129 | 1.00 | KDR (0.93) | KDRPDGFRBPRKAA1FGFR1PRKAA2 | |
| Su-014813 SCHEMBL902507 | 0.96 | KDR (1.00) | KDRPDGFRBPRKAA1FGFR1PRKAA2 | |
| Su-014813 SCHEMBL2334599 | 0.96 | KDR (1.00) | KDRPDGFRBPRKAA1FGFR1PRKAA2 | |
| Su-014813 SCHEMBL4500929 | 0.96 | KDR (1.00) | KDRPDGFRBPRKAA1FGFR1PRKAA2 | |
| Su-014813 SCHEMBL2334610 | 0.96 | KDR (1.00) | KDRPDGFRBPRKAA1FGFR1PRKAA2 | |
| Su-014813 SCHEMBL4500940 | 0.96 | KDR (1.00) | KDRPDGFRBPRKAA1FGFR1PRKAA2 | |
| Su-014813 SCHEMBL1249521 | 0.96 | KDR (1.00) | KDRPDGFRBPRKAA1FGFR1PRKAA2 | |
| SCHEMBL13711974 | 0.89 | PDGFRB (0.86) | KDRPDGFRBPRKAA1FGFR1PRKAA2 | |
| SCHEMBL6726631 | 0.88 | PDGFRB (0.83) | KDRPDGFRBPRKAA1FGFR1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317715-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS HOLDINGS, INC. | 2010-12-16 | — | — | US | disclosed |
| EP-1670785-B1 | SALTS AND POLYMORPHS OF A PYRROLE-SUBSTITUTED INDOLINONE COMPOUND | PHARMACIA & UPJOHN CO LLC (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7247627-B2 | non-hygroscopic, crystalline anhydrous maleate salt of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | PHARMACIA & UPJOHN COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1670785-A1 | SALTS AND POLYMORPHS OF A PYRROLE-SUBSTITUTED INDOLINONE COMPOUND | Pharmacia & Upjohn Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005033098-A9 | Salts and polymorphs of a pyrrole-substituted indolinone compound | PHARMACIA & UPJOHN CO LLC (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20050118255-A1 | non-hygroscopic, crystalline anhydrous maleate salt of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | BLASKO ANDREI (US) | 2005-06-02 | — | — | US | disclosed |
| WO-2005033098-A1 | SALTS AND POLYMORPHS OF A PYRROLE-SUBSTITUTED INDOLINONE COMPOUND | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317715-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | GRM5, GRIK5, PAK5 | KDR 4812/4885PDGFRB 3065/4885KIT 4475/4885 |
| US-20050118255-A1 | non-hygroscopic, crystalline anhydrous maleate salt of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC5A11, INF2 | KDR 3323/4885PDGFRB 4295/4885KIT 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.